TERLIVAZ
Peakterlipressin
NDAINTRAVENOUSPOWDERPriority Review
Approved
Sep 2022
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
4
Data completeness
4/8 — Partial
Priority Review
TERLIVAZ (terlipressin) is vasopressin receptor agonists [moa]. First approved in 2022.
Drug data last refreshed 3h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TERLIVAZ (terlipressin) is a vasopressin receptor agonist administered intravenously as a powder formulation. It works by stimulating vasopressin receptors to increase vasoconstriction and reduce portal pressure in patients with hepatic conditions. The drug was approved in September 2022 and is currently in peak commercial lifecycle.
Peak10.5 years to LOE
Peak-stage asset with no identified direct competitors suggests strong market position and potential for stable commercial team growth.
Mechanism of Action
Vasopressin Receptor Agonists
Pharmacologic Class:
Vasopressin Receptor Agonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (4)
Continuous Infusion Terlipressin for Patients With Cirrhosis and Refractory Ascites
Started Jul 2017
6 enrolled
CirrhosisAscites Hepatic
Continuos Terlipressin Infusion in Septic Shock
Started Jan 2013
1,000 enrolled
Septic Shock
Follow-up of Glypressin (Terlipressin) Clinical Efficacy in the Treatment of Bleeding Oesophageal Varices
Started Nov 2010
20 enrolled
Gastrointestinal BleedingOesophageal Varices
A Study of Terlipressin in Patients With Hepatorenal Syndrome Type 1
Started Nov 2007
8 enrolled
Hepatorenal Syndrome Type 1
Career Relevance
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.